澳大利亚最大制药公司CSL已与特朗普政府签署协议，承诺在美国降低药品价格以换取关税减免1。作为九家签署类似协议的全球生物技术和制药公司之一，CSL同意为美国医疗补助计划提供药品折扣，价格与其他发达国家相当1。此举旨在规避对澳大利亚制药品征收的100%关税1。
根据协议，CSL还承诺在伊利诺伊州投资15亿美元扩建血浆疗法工厂1。九家新签约公司在近期内共承诺投资196亿美元用于美国制造1。特朗普声称，26家公司占美国医药市场的90%已签署最惠国折扣协议1。值得注意的是，澳大利亚在100%关税中未获得如欧盟、日本、韩国和瑞士那样的15%优惠1。
CSL表示不预期该协议在2027财年产生任何重大影响1。根据哈佛医学院和城市研究所研究员的估计，若政策适用于82种高成本品牌药物，可使各州年度医疗补助支出减少超80亿美元1。
Australia's largest pharmaceutical company CSL has signed an agreement with the Trump administration committing to reduce medicine prices in the United States in exchange for tariff relief 1. As one of nine global biotech and pharmaceutical companies to enter into similar arrangements, CSL has agreed to provide discounts for the U.S. Medicaid program at prices comparable to those in other developed nations 1. The company has also pledged a $1.5 billion investment to expand its plasma therapy manufacturing facility in Illinois under a "localization agreement" 1.
The deal allows CSL to sidestep a 100% tariff on Australian pharmaceutical products that would otherwise apply this year 1. Together, the nine newly signing companies have committed $19.6 billion in U.S. manufacturing investments in the near term 1. Trump has claimed that 26 companies representing 90% of the American pharmaceutical market have now signed agreements for most-favored-nation pricing discounts 1.
CSL indicated it does not expect the agreement to produce "any significant impact" on its 2027 financial year results 1. However, researchers from Harvard Medical School and the Urban Institute have estimated that if the policy applies to 82 high-cost brand-name drugs, it could reduce annual Medicaid spending across U.S. states by more than $8 billion 1.
评论
还没有评论，欢迎留下第一条。